Publications by authors named "Ines Sebastiao"
Type 2 diabetes (T2D) is a modern socioeconomic burden, mostly due to its long-term complications affecting nearly all tissues. One of them is the brain, whose dysfunctional intracellular quality control mechanisms (namely autophagy) may upregulate apoptosis, leading to cognitive dysfunction and Alzheimer disease (AD). Since impaired brain insulin signaling may constitute the crosslink between T2D and AD, its restoration may be potentially therapeutic herein.
View Article and Find Full Text PDFLong-acting glucagon-like peptide-1 (GLP-1) analogues marketed for type 2 diabetes (T2D) treatment have been showing positive and protective effects in several different tissues, including pancreas, heart or even brain. This gut secreted hormone plays a potent insulinotropic activity and an important role in maintaining glucose homeostasis. Furthermore, growing evidences suggest the occurrence of several commonalities between T2D and neurodegenerative diseases, insulin resistance being pointed as a main cause for cognitive decline and increased risk to develop dementia.
View Article and Find Full Text PDFArticle Synopsis
- Type 2 diabetes (T2D) and Alzheimer’s disease (AD) are interconnected health issues, with T2D affecting millions of elderly individuals and increasing the risk for AD due to shared complications.
- Research suggests that insulin resistance, a key feature of T2D, also occurs in AD, leading to the classification of AD as "type 3 diabetes" and indicating that treatments for T2D could benefit AD patients.
- The review focuses on the overlap in insulin signaling related to the formation of amyloid plaques and neurofibrillary tangles in AD, and discusses the potential of certain anti-T2D medications, especially GLP-1 receptor agonists, to protect against cognitive decline and dementia.